Lauren Carter MS

Lauren Carter was born and raised in Fort Worth, Texas, and fled the heat to attend the University of Washington with an eye toward medical school. Organic chemistry lead to a reconsideration of that particular career path, but a long-standing fascination with cellular and molecular biology kept her in the lab, beginning in the Department of Pathology. After graduating in 2000 with a B.S. in Cellular and Molecular Biology and a B.A. in English Literature, Lauren joined Corixa Corporation’s Protein Biochemistry group, eventually transitioning to Analytical Biochemistry. Following GSK’s acquisition of Corixa, Lauren transitioned to the Infectious Disease Research Institute (IDRI), Process Sciences group. There she successfully developed and produced a therapeutic vaccine for Leishmaniasis, which was tested in clinical trials in the Sudan and India. Following several years at IDRI, Lauren shifted gears from the non-profit world to Contract Manufacturing, joining CMC Biologics, Downstream Process Development group. There she was able to assist with the development and cGMP manufacturing of several projects, including a commercial-stage project. Following CMC Biologics, Lauren joined Theraclone Sciences, Process Sciences group, where she developed and cGMP manufactured a monoclonal antibody intended for prophylactic use to prevent Cytomegalovirus infection.

Lauren has a certificate in Biotechnology Project Management from the University of Washington and recently completed a Master of Science in Translational Pharmaceutics at the University of Washington Department of Bioengineering (2015).

Lauren specializes in protein purification, formulation, and characterization, with an emphasis on process development and cGMP manufacturing. Her current responsibilities include running the Structured Science Protein Core, producing and characterizing quality proteins for both internal investigators as well as external collaborators.